Skip to main content
ELTX
NASDAQ Life Sciences

Elicio Therapeutics Reports Going Concern Doubt, Significant Dilution Amidst Clinical Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$10.69
Mkt Cap
$190.636M
52W Low
$4.6
52W High
$14.93
52W Position info
132% above low
Off High info
28% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ELTX has more than doubled off its 52-week low of $4.6.

Summary

Elicio Therapeutics' 10-K reveals a 'going concern' warning and a short cash runway, necessitating significant dilutive financing in 2025, despite positive clinical data for its lead cancer immunotherapy.


Key Events · Financing and Capital Events · ELTX

  • Going Concern Warning Issued

    The company's independent auditor and management have raised substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

  • Limited Cash Runway

    Current cash and cash equivalents of $18.6 million as of December 31, 2025, are projected to fund operations only into the third quarter of 2026.

  • Significant Dilutive Financing in 2025

    Elicio Therapeutics raised approximately $55.6 million in 2025 through various offerings and a convertible note conversion, resulting in a substantial 61% increase in outstanding common shares.

  • Positive Clinical Progress for ELI-002 7P

    The Phase 2 AMPLIFY-7P study for mKRAS-driven pancreatic cancer received a positive recommendation from the Independent Data Monitoring Committee to continue to final analysis, with robust T-cell responses and antigen spreading observed. Final DFS analysis is anticipated in H1 2026.


Analysis · ELTX · Life Sciences

Elicio Therapeutics' annual report highlights critical financial challenges, including an explicit 'going concern' warning and a limited cash runway extending only into the third quarter of 2026. The company undertook substantial dilutive financing activities in 2025, raising approximately $55.6 million through ATM offerings, public offerings, and a convertible note conversion, which led to a significant 61% increase in outstanding shares. While the company reported positive clinical progress for its lead candidate ELI-002 7P, demonstrating robust T-cell responses and antigen spreading in its Phase 2 study, these advancements are overshadowed by the immediate need for additional capital to sustain operations. Investors should closely monitor future financing efforts and the upcoming final DFS analysis for ELI-002 7P, as the company's financial viability remains a primary concern.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELTX was trading at $10.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.6M. The 52-week trading range was $4.60 to $14.93. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELTX - Latest Insights

ELTX
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.45 info
Change: +$0.045 (+3%) info
Market Cap: $41.045M info
ELTX
Nov 05, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.45 info
Change: +$0.045 (+3%) info
Market Cap: $41.045M info
ELTX
Oct 23, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.45 info
Change: -$0.330 (-19%) info
Market Cap: $41.045M info
ELTX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $1.45 info
Change: -$1.65 (-53%) info
Market Cap: $41.045M info
ELTX
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.45 info
Change: -$1.81 (-56%) info
Market Cap: $41.045M info